Compare LTC & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LTC | CLDX |
|---|---|---|
| Founded | 1992 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.9B |
| IPO Year | 1994 | 1995 |
| Metric | LTC | CLDX |
|---|---|---|
| Price | $39.10 | $29.51 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $39.00 | ★ $44.50 |
| AVG Volume (30 Days) | 339.5K | ★ 911.7K |
| Earning Date | 05-27-2026 | 05-28-2026 |
| Dividend Yield | ★ 5.84% | N/A |
| EPS Growth | ★ 23.53 | N/A |
| EPS | ★ 2.52 | N/A |
| Revenue | ★ $262,854,000.00 | $12,743,000.00 |
| Revenue This Year | N/A | $97.61 |
| Revenue Next Year | $13.24 | $252.01 |
| P/E Ratio | $15.48 | ★ N/A |
| Revenue Growth | 25.26 | ★ 87.78 |
| 52 Week Low | $31.70 | $14.40 |
| 52 Week High | $40.80 | $31.85 |
| Indicator | LTC | CLDX |
|---|---|---|
| Relative Strength Index (RSI) | 55.70 | 58.54 |
| Support Level | $38.08 | $24.70 |
| Resistance Level | $40.43 | $30.90 |
| Average True Range (ATR) | 0.82 | 1.57 |
| MACD | -0.15 | 0.17 |
| Stochastic Oscillator | 44.87 | 71.04 |
LTC Properties Inc is a real estate investment trust. It invests in seniors housing and health care properties, mainly through ownership, sale-leasebacks, mortgage financing, joint ventures, construction financing, and structured finance solutions, including preferred equity, bridge, and mezzanine lending. The company's investment portfolio comprises several properties located throughout the USA, the majority of which are seniors housing and skilled nursing properties. The firm conducts and manages its business as two operating segments: Real Estate Investments, which generates maximum revenue, and SHOP.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.